Dr Conroy was a cofounder of Therakind and was subsequently appointed CEO leading the company’s strategy, identification and negotiation of key agreements and commercial opportunities and overseeing day-to day business operations, including driving the approval in US and EU of three Therakind drug products to date

An expert in the identification, evaluation, management and commercialisation of pharmaceutical and biotechnology products across multiple areas.

Prior to Therakind, she worked as a consultant specialising in maximising scientific value to early start up programmes, technology transfer, medical affairs, commercial exploitation of existing products and an independent funding assessor of start-ups.

Prior to consultancy, Susan worked for 9 years in large and small pharma, evaluating and commercialising research programmes, clinical research, market opportunities and novel therapeutic areas.

Susan has a PhD in Molecular Biology from London University and carried out post-doctoral research in oncology at University College London.

Susan is a Trustee of Anthony Nolan - a large UK-based revenue stem cell charity where she sits on the Audit & Finance and the Governance & Risk Committees.

Louise joined Therakind with more than 20 years of experience in pharmaceutical regulatory affairs and regulatory compliance, with tenures with Ineos Healthcare, Gilead and ML Laboratories PLC

Extensive knowledge of EU/US clinical trial regulations as well as medical device licensing procedures and regulations, directives and guidelines.

Facilitated regulatory authority inspections of both UK- and US-based investigator sites and GMP and device manufacturing facilities.

Significant experience in managing compliance programmes for all phases of global clinical trials and 10 years of experience in pharmacovigilance for licensed and investigational medicinal products.

Samantha joined Therakind in 2014 as Financial Controller with responsibility over all aspects of the financial management of the company including planning and forecasting, internal control, statutory reporting and company secretarial duties.

Supports business development and plays a key role in negotiation and management of commercial partnerships.

Provides close counsel to CEO and the Board of Directors with timely and accurate information critical to the decision-making process and strategic direction of the company.

Finance specialist with proven track record in financial and management accounting and systems development within the software industry, and multi-sector across a number of high-profile clients.

Qualified Chartered Accountant with ‘Big 4’ training. Degree in Economics from Cambridge University.

Dr. Penton joined Therakind with over 20 years of experience in pharmaceutical development and project management.

Extensive experience in the management of all aspects of pharmaceutical development with specific expertise in outsourcing and managing CRO activities.

Expert in writing and compiling CMC components of regulatory packages with significant experience with EU, US, and Japanese programmes and has acted as a pharmaceutical expert for a number of EU submissions.

Previously Formulation Development Scientist for Rhone Poulenc Rorer (now Sanofi Aventis) and Director of Pharmaceutical Development at Vectura (previously Innovata Biomed) where she was responsible for early-phase and late-phase pharmaceutical development and commercialisation projects.

Degree in Pharmacy and PhD in pharmaceutical drug delivery from The University of Manchester.

·Chris brings over 35 years of MedTech experience, particularly the transfer of devices from R&D into production and subsequent scale-up to large-volume manufacture.

He held senior leadership roles and delivered projects for medical device, biotech and pharma companies including Sphere Medical, Pfizer, Innovata Biomed, Allergan, Ocular Sciences, Cellnovo and Owen Mumford/Abbvie.

Expertise spans a series of delivery platforms and routes of administration including inhaled, parenteral and patch pump drug delivery. Project Manager for AbbVie’s second-generation Humira autoinjector industrialisation.

Consultancy across the industry has also included emerging technologies such as wearables and biosensing, as well as supporting due diligence prior to investment or M&A.

He is both apprentice-trained as a toolmaker and degree qualified in Design Management, achieving awards for outstanding performance in both endeavours.